Optellum Ltd. Company Research Report

---

Company Overview

• Name: Optellum Ltd.

• Mission: Optellum was founded with the mission to ensure every lung disease patient is diagnosed and treated at the earliest possible stage, thus increasing the chances of cure. The company aims to redefine early intervention in diseases like lung cancer by enabling clinicians to make precise decisions, thereby giving patients the best chance to fight against the disease.

• Founded: No information is available

• Founders: No information is available

• Key People: No information is available

• Headquarters:

• Optellum Ltd. is located at the Oxford Centre for Innovation, Oxford, OX1 1BY, United Kingdom.

• Optellum Inc. is located at the TMC Innovation Institute, 2450 Holcombe Blvd, Suite X, Houston, TX 77021, United States.

• Number of Employees: No information is available

• Revenue: No information is available

• Company Known For: Optellum is known for being a leading innovator in artificial intelligence (AI) and medical imaging technology designed to assist in lung cancer diagnosis and treatment.

Products

• Virtual Nodule Clinic (VNC):

• Description: The Virtual Nodule Clinic is the world’s first AI-powered clinical decision support software for early lung cancer diagnosis. It is clinically validated to enhance lung cancer diagnosis and improve patient management and outcomes.

• Key Features:

• Patient Discovery AI: Enhances the ability to identify more patients at risk.

• Tracking and Management: Facilitates timely patient care.

• Lung Cancer Prediction AI: Supports optimal decision-making with FDA and CE mark clearance, making it reimbursable.

Recent Developments

• New Products and Features:

• The Virtual Nodule Clinic with Patient Discovery AI, Lung Cancer Prediction AI, and Tracking and Management features.

• Partnerships and Collaborations:

• Collaboration with Johnson & Johnson's Lung Cancer Initiative to transform early lung cancer treatment using AI.

• Partnership with GE Healthcare to drive AI-powered lung cancer diagnosis.

• Notable Achievements:

• Optellum's solutions are now available on the UK Government's G-Cloud 14 framework.

• Awarded a grant by the National Institute for Health and Care Research (NIHR) to advance AI imaging technology for early lung cancer diagnosis.

• Achieved ISO 27001:2022 certification, reaffirming its commitment to cybersecurity.

• Press and Media Coverage:

• Optellum has been featured by UConn Health for its integration into their system, showing improved early-stage cancer detection.

• Regulatory Approvals:

• Attained FDA 510(k), CE-MDR, and UKCA clearance for the Virtual Nodule Clinic software platform.

Conclusion

Optellum Ltd. continues to be at the forefront of AI-driven healthcare solutions, with a specific focus on enhancing early diagnosis and management of lung cancer. Through strategic collaborations and cutting-edge technological advancements, the company aims to revolutionize lung cancer care and optimize patient outcomes.